Under construction – not a live service
Sign in
Taking people in DenmarkPhase 1/2

Imaging how the heart uses fuel in people with heart failure

Tests a special MRI scan of heart metabolism in adults with heart failure.

Key facts

Who runs it
Region Midtjylland
Where
Aarhus N, DenmarkSee the site
Registry title
Investigation of cardiac metabolism in patients with heart failure using hyperpolarized MRI
Status
Recruiting
Phase
Phase 1/2
People taking part
30 people, planned
Started
1 Dec 2019
Planned end
1 Jul 2026
Type of study
Interventional
Record updated
13 February 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with long-lasting heart failure, including reduced or preserved pumping function, to study how the heart uses pyruvate with a special MRI scan.

Age
Over 18 years
Sex
All sexes
Disease stage
Chronic heart failure with a left ventricular ejection fraction (LVEF) of 10 – 60 %. One substudy (1A) needs ischemic heart disease and referral to viability testing.
Earlier treatment
Before the first study, people cannot be on more than 50% of the target dose of ACE-inhibitor and betablockers. This does not apply to substudy 1A.
Biomarker or test result
Neutrophil count (ANC) at least 1.500/uL, platelet count >100/uL, serum creatinine up to 1.5 x UNL or creatinine clearance at least 30 ml/min. Women who can have children need a negative pregnancy test.

Main reasons for not taking part

  • Cannot or will not receive heart failure therapy
  • Uncontrolled serious medical condition such as uncontrolled heart disease, diabetes or hypertension
  • eGFR below 30 mL/min
  • Insulin dependent diabetes
  • Intolerance to pyruvate

The registry criteria, word for word

Show all 2 criteriaShow less

Who can take part

  • Chronic heart failure (Heart failure with both reduced and preserved EF are allowed) > 18 years of age. Left ventricular Ejection Fraction (LVEF) of 10 – 60 % Adequate hematologic and organ function, i.e. ANC at least 1.500/uL Platelet count >100/uL Se creatinine up to 1.5 x UNL or creatinine clearance at least 30 ml/min Women who are not postmenopausal or surgically sterile must have a negative serum or urine pregnancy test performed at time of inclusion in the study. Safe and highly effective contraception must be used throughout the study meaning either hormonal anti-conception or an anti-fertility intrauterine device. If the partner is non fertile or the patient has no sexual activities, this is also accepted. Non-insulin dependent Diabetes mellitus is allowed Danish speaking Able and willing to comply after informed consent For substudy 1A only: Ischemic heart disease and referral to viability testing at the Department of Clinical Physiology and Nuclear Medicine at Aarhus University Hospital, Skejby

Who cannot take part

  • Not able or willing to receive heart failure therapy Patients not willing to participate Uncontrolled serious medical condition, such as uncontrolled heart disease, uncontrolled diabetes, intestinal obstruction, uncontrolled hypertension, or recent cerebral ischemia Receiving more than 50% of taget dose of ACE-inhibitor and betablockers before inclusion in study 1 (this does not apply for substudy 1A) Estimated Glomerular Filtration Rate (eGFR) <30 mL/min Insulin dependent Diabetes Mellitus Intolerance to Pyruvate

Where in Denmark

  • Aarhus UniversitetshospitalAarhus N, DenmarkTaking people

About the trial

What the trial wants to find out

To visualize and quantify pyruvate metabolism of the heart in patients with heart disease and correlate it to current clinical diagnostic scanning modalities.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
Clinical and pathophysiological aspects of visualization of metabolic flux in the failing human heart using hyperpolarized [1-13C]-pyruvate cardiac magnetic resonance
Plain-language title
Imaging how the heart uses fuel in people with heart failureGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
13 February 2026